Antibodies

20 Jul 2009 Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus
16 Jul 2009 Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting
16 Jul 2009 GENMAB ANNOUNCES LIFT OF ZALUTUMUMAB PARTIAL CLINICAL HOLD
15 Jul 2009 BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
15 Jul 2009 Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
15 Jul 2009 Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID(TM) with rHuPH20 Enzyme
15 Jul 2009 XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
13 Jul 2009 NovImmune successfully completes NI-0801 Phase I clinical study
13 Jul 2009 MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
10 Jul 2009 InNexus and Genhelix to Combine Antibody Development and Manufacturing Resources
09 Jul 2009 RECRUITMENT COMPLETED IN ARZERRA™ (OFATUMUMAB) PIVOTAL CLL STUDY
09 Jul 2009 DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SUPPORT USE OF RAXIBACUMAB (ABTHRAX™) FOR THE TREATMENT OF INHALATION ANTHRAX
09 Jul 2009 Medarex and Lonza Sign Collaboration Agreement for the Supply of Antibody-Based Products
08 Jul 2009 ENBREL to Add Indication of Juvenile Idiopathic Arthritis (JIA)
08 Jul 2009 Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
06 Jul 2009 Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Zevalin
06 Jul 2009 MorphoSys Secures Full-Term of Strategic Alliance
03 Jul 2009 Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
03 Jul 2009 ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402
02 Jul 2009 Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
01 Jul 2009 Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
30 Jun 2009 Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
29 Jun 2009 ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R
26 Jun 2009 Cimzia®, the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis
26 Jun 2009 SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top